In-hospital outcomes of patients undergoing concomitant aortic and mitral valve replacement in Germany

 Open in a separate windowOBJECTIVESTo evaluate in-hospital outcomes of concomitant mitral valve replacement (MVR) in patients undergoing conventional aortic valve replacement due to aortic stenosis in a nationwide cohort.METHODSAdministrative data from all patients with aortic stenosis undergoing conventional aortic and concomitant MVR (reason for MVR not specified) between 2017 and 2018 in Germany were analysed.RESULTSA total of 2597 patients with a preoperative logistic EuroScore of 9.81 (standard deviation: 8.56) were identified. In-hospital mortality was 6.8%. An in-hospital stroke occurred in 3.4%, acute kidney injury in 16.3%, prolonged mechanical ventilation of more than 48 h in 16.3%, postoperative delirium in 15.8% and postoperative pacemaker implantation in 7.6% of the patients. Mean hospital stay was 16.5 (standard deviation: 12.1) days. Age [odds ratio (OR): 1.03; P = 0.019], New York Heart Association class III or IV (OR: 1.63; P = 0.012), previous cardiac surgery (OR: 2.85, P = 0.002), peripheral vascular disease (OR: 2.01, P = 0.031), pulmonary hypertension (OR: 1.63, P = 0.042) and impaired renal function (glomerular filtration rate <15, OR: 3.58, P = 0.001; glomerular filtration rate <30, OR: 2.51, P = 0.037) were identified as independent predictors for in-hospital mortality.CONCLUSIONSIn this nationwide analysis, concomitant aortic and MVR was associated with acceptable in-hospital mortality, morbidity and length of in-hospital stay. The regression analyses may help to identify high-risk patients and further optimize treatment strategies.     

Late results after mitral valve replacement with Mosaic bioprosthesis in patients aged 65 years or younger

Open in a separate window OBJECTIVESAlthough in younger patients indications for biological prosthesis implantation in mitral valve replacement remain controversial, recently bioprostheses use increased considerably. We present late results obtained with the Medtronic Mosaic bioprosthesis in patients aged 65 years or younger. METHODSBetween 2007 and 2017, 67 mitral Mosaic bioprostheses were implanted in patients aged 65 years or younger (58.5 ± 6.4 years). Follow-up extended up to 13 years. Survival, freedom from structural valve degeneration, endocarditis, thromboembolic events and reoperation were considered as main clinical end points evaluated at 1, 5 and 10 years.RESULTSThe mean follow-up was 4.7 ± 2.8 years. Overall mortality rate was 12%. At 1, 5 and 10 years, survival was 94 ± 3%, 89 ± 4% and 77 ± 9%, respectively. Freedom from structural valve degeneration was 100%, 94 ± 4% and 71 ± 21%. Freedom from endocarditis was 95 ± 3%, 90 ± 6% and 84 ± 8%. Freedom from thromboembolic events was 94 ± 3%, 90 ± 5% and 90 ± 5%. Freedom from reoperation was 94 ± 3%, 87 ± 5% and 65 ± 19%.CONCLUSIONSMosaic bioprosthesis appears a valid mitral valve substitute even when employed in ≤65-year-old patients.     

Hemolysis after mitral valve replacement with mechanical valve prostheses

OBJECTIVE: We evaluated effects of type, size, and orientation of mechanical mitral valve prostheses on hemolysis. METHODS: Subjects were 84 patients who had undergone mitral valve replacement. Lactate dehydrogenase was mainly used as a marker of hemolysis and was measured before surgery, 1 month after surgery, and in the late postoperative period. RESULTS: Valves used included 16 Medtronic-Hall, 32 St. Jude Medical, and 36 CarboMedics valves. Medtronic-Hall valves caused less hemolysis than St. Jude Medical or CarboMedics valves in the late postoperative period. This resulted because hemolysis due to Medtronic-Hall valves was more severe 1 month after surgery than in the late postoperative period and because hemolysis due to St. Jude Medical or CarboMedics valves was more severe in the late postoperative period than 1 month after surgery. One reason for this finding is that cardiac output was greater in the late postoperative period than 1 month after surgery, making regurgitation through the pivots of bileaflet valves more severe. The orifice area and the orientation of prostheses did not affect hemolysis. CONCLUSION: St. Jude Medical or CarboMedics valves caused more severe hemolysis than Medtronic-Hall valves in the late postoperative period.     

Perivalvular leakage 25 years after initial mitral valve replacement with a Björk-Shiley prosthesis

An 80-year-old woman had undergone initial mitral valve replacement using a Björk-Shiley mechanical valve owing to mitral stenosis 25 years earlier. Suddenly, she had anemia and an increased lactic dehydrogenase (LDH) level. Transesophageal echography (TEE) showed perivalvular leakage. In a redo operation, two side-by-side stitches of the valve on the posterior annulus were loosened without cutting and the sewing cuff at that site was floated over the annulus, leading to the perivalvular leakage. The valve was easily removed; and round, hard, degenerative calcified tissue composed of remnant mitral valve in the suture site during the initial operation was found just under the sewing cuff. After resection of this calcified round tissue, a 25-mm bioprosthesis was put in place. Her postoperative recovery was uneventful, and 47 days after surgery she was discharged without perivalvular leakage or anemia.     

An alternative valve for mitral valve replacement in young children: using an NO-REACT® INJECTABLE BIOPULMONIC™ prosthesis as a mitral valve replacement in a 14-month-old child

Mitral valve replacement in infants is challenging and there are limited alternative valves available. Since the Boston group published their first report on alternative valves for mitral valve replacement in infants, there has been a growth in the literature on the topic, mostly based on the use of a stented bovine jugular vein graft (Melody^® valve). The challenges of the Melody valve are firstly in its length of 28 mm unexpanded, which has the potential to cause left ventricular outflow tract obstruction, and secondly, the valve needs mechanical dilatation, which is laborious. A modified No-React^® Injectable Biopulmonic™ Prosthesis (Bio Integral Surgical, Inc., Mississauga, ON, Canada) which is shorter (19 mm) and simpler in that it is self-expanding was implanted in a 14-month-old child to replace her mitral valve. The operation was successful and the short-term function of the prosthesis is good.     

吸入一氧化氮对心瓣膜置换术后肺动脉高压患者血流动力学的影响

目的：观察吸入一氧化氮（ＮＯ）对心瓣膜置换术后肺动脉高压患者血流动力学的影响。方法：选择９例心瓣膜置换术后伴肺动脉高压的病人，吸入ＮＯ０．００３％，观察三个时象点：吸入ＮＯ前；开始吸入ＮＯ后１５分钟；停止吸入ＮＯ后１５分钟。结果：吸入ＮＯ能显著降低肺动脉压和肺循环阻力指数（Ｐ＜０．０１），停止吸入ＮＯ１５分钟后，肺动脉压和肺循环阻力指数恢复到原有水平。在整个观察过程中，心率、平均动脉压、中心静脉压、肺动脉楔压、体循环阻力指数和心脏指数均无显著变化（Ｐ＞０．０５）。结论：吸入ＮＯ具有选择性肺血管扩张作用，是治疗心瓣膜置换术后肺动脉高压的较理想药物。     

保留瓣下结构对二尖瓣置换术后机械瓣血流动力学的影响

目的探讨保留瓣下结构对二尖瓣置换术(MVR)后机械瓣血流动力学的影响. 方法对100例二尖瓣狭窄为主的患者施行MVR,根据术中对自体瓣膜处理的方式不同分为全部保留瓣下结构组(Ⅰ组、23例),全部切除瓣下结构组(Ⅱ组、27例),保留前瓣组(Ⅲ组、22例),保留后瓣组(Ⅳ组、28例),20例健康志愿者作为正常组.均采用二维超声心动图、彩色多普勒技术,对各组患者随访,以正常人作为对照,测量二尖瓣口血流动力学参数,比较各组间的差别. 结果Ⅰ～Ⅳ组二尖瓣口血流动力学的各种参数与正常组比较差别具有显著性意义(P＜0.05),而各种参数在Ⅰ～Ⅳ组之间比较差别无显著性意义(P＞0.05). 结论在慢性二尖瓣狭窄为主的患者中,研究涉及的各种保留瓣下结构方法之间,保留与不保留瓣下结构之间,术后中期的机械瓣血流动力学无明显差别.     

Aortic valve replacement for aortic stenosis in patients with concomitant mitral regurgitation: should the mitral valve be dealt with?

Co-existent mitral regurgitation may adversely influence both morbidity and mortality in patients undergoing aortic valve replacement for severe aortic stenosis. Whilst it is accepted that concomitant mitral intervention is required in severe, symptomatic mitral regurgitation, in cases of mild–moderate non-structural mitral regurgitation, improvement may be seen following aortic valve replacement alone, avoiding the increased risk of double-valve surgery. The exact benefit of such a conservative approach is, however, yet to be adequately quantified. We performed a systematic literature review identifying 17 studies incorporating 3053 patients undergoing aortic valve replacement for aortic stenosis with co-existing mitral regurgitation. These were meta-analysed using random effects modelling. Heterogeneity and subgroup analysis were assessed. Primary end points were change in mitral regurgitation severity and 30-day, 3-, 5- and 10-year mortality. Secondary end points were end-organ dysfunction (neurovascular, renal and respiratory), and the extent of ventricular remodelling following aortic valve replacement. Our results revealed improvement in the severity of mitral regurgitation following aortic valve replacement in 55.5% of patients, whereas 37.7% remained unchanged, and 6.8% worsened. No significant difference was seen between overall data and either the functional or moderate subgroups. The overall 30-day mortality following aortic valve replacement was 5%. This was significantly higher in moderate–severe mitral regurgitation than nil–mild mitral regurgitation both overall (p = 0.002) and in the functional subgroup (p = 0.004). Improved long-term survival was seen at 3, 5 and 10 years in nil–mild mitral regurgitation when compared with moderate–severe mitral regurgitation in all groups (overall p < 0.0001, p < 0.00001 and p = 0.02, respectively). The relative risk of respiratory, renal and neurovascular complications were 7%, 6% and 4%, respectively. Reverse remodelling was demonstrated by a significant reduction in left-ventricular end-diastolic diameter and left-ventricular mass (p = 0.0007 and 0.01, respectively), without significant heterogeneity. No significant change was seen in left-ventricular end-systolic diameter (p = 0.10), septal thickness (p = 0.17) or left atrial area (p = 0.23). We conclude that despite reverse remodelling, concomitant moderate–severe mitral regurgitation adversely affects both early and late mortality following aortic valve replacement. Concomitant mitral intervention should therefore be considered in the presence of moderate mitral regurgitation, independent of the aetiology.     

Long-term survivors after valve replacement with a Starr-Edwards mitral disk valve prosthesis

We report four long-term survivors after valve replacement with a Starr-Edwards (S-E) mitral caged-disk valve. A model 6520 disk valve, size 3M, had been used in all of the four patients. Of the four patients, three underwent replacement of the disk valves 23, 24, and 26 years after mitral valve replacement (MVR), respectively. A pacemaker was implanted in the remaining patient 33 years after MVR. The S-E disk valves were considered hemodynamically slightly stenotic compared with modern bileaflet valves. No disk wear was detected in any of the three explanted valves, and in the remaining patient, a noninvasive evaluation of the disk showed that it was functioning normally. These results suggest the favorable long-term durability of the S-E disk valve.     

Hemodynamic evaluation of stentless mitral valve replacement

The purpose of this study was to evaluate the perioperative and postoperative hemodynamic function of recently introduced stentless mitral valves (SMVs). Forty-two selected patients who had received the SMV since 1997 had preoperative, postoperative, and follow-up transthoracic echocardiographic (TTE) examinations. Transesophageal echocardiography (TEE) was applied routinely during the operation as well as postoperatively if indicated. Adequate SMV function was seen in all patients perioperatively. Echocardiographic prediction of valve size and of papillary muscle distances was correct in 37 of 42 patients. Transvalvular blood flow velocities were 1.6 +/- 0.2 m/s postoperatively versus 1.8 +/- 0.3 m/s at 1 year and 1.7 +/- 0.3 m/s at 3-year follow-up. Mean transvalvular gradients were 4.3 +/- 1.6, 3.8 +/- 1.9, and 4.7 +/- 1.1 mm Hg, respectively. TEE and TTE are extremely useful to assist SMV implantation as well as for regular follow-up evaluation. The hemodynamic function after SMV implantation with preservation of the annulo-ventricular continuity is promising.     

Long-term experience with the Sorin Bicarbon and Edwards Mira mechanical valve prostheses in the mitral position

OBJECTIVE: Sorin Bicarbon (SB) and Edwards Mira (EM) valves have an identical mechanical design but different sewing cuffs. The purpose of this retrospective study was to analyze the long-term clinical and echocardiographic outcomes after mitral valve replacement with these two valves in a combined population of patients. METHODS: We retrospectively reviewed records of 73 patients who underwent mitral valve replacement using SB (n = 19) or EM (n = 54) valves. Preoperatively, 49 patients (68.1%) were in New York Heart Association (NYHA) functional class III or IV. Concomitant procedures were performed in 52 patients (71.2%). Early and late postoperative echocardiography was performed in 69 and 57 patients, respectively. RESULTS: Operative mortality was 4.1%, and early morbidity was 9.6%. Overall patient survival at 9 years was 85.1% +/- 4.8%. Actuarial freedom from valve-related death was 95.4% +/- 2.6% at 9 years. As shown by Doppler echocardiography, the early and late mean transprosthetic pressure gradients were 3.4 +/- 1.4 mmHg and 3.8 +/- 2.1 mmHg, respectively. At the end of follow-up, 98.4% of survivors were in NYHA class I or II. CONCLUSION: The Sorin Bicarbon and, Edwards Mira mechanical valves in the mitral position provide satisfactory long-term clinical and echocardiographic performance.     

Intermediate-term outcomes of aortic valve replacement with bioprosthetic or mechanical valves in patients on hemodialysis

ObjectiveTo investigate the influence of choice of prosthesis (bioprosthetic valves or mechanical valves) on intermediate-term outcomes in patients on hemodialysis undergoing aortic valve replacement (AVR).MethodsA multi-institutional retrospective cohort study was conducted in 18 Japanese centers. All adult patients on chronic hemodialysis who underwent AVR from 2008 and 2015 were included (n = 491). The early and late results were compared between groups. The hazard ratios were calculated using Cox regression and Fine–Gray models with adjustment for propensity score based on 41 confounders. The mean follow-up period was 2.5 ± 2.1 years (up to 8.3 years) with 98% completeness.ResultsThere were 323 patients who received a bioprosthetic valve (group B), and 168 patients who received a mechanical valve (group M). There was no significant difference for in-hospital death rate between groups (group B: 12.1%; group M: 8.9%; P = .29). The overall survival rate at 5 years after surgery was 39.3% in group B and 50.4% in group M (P = .42). Freedom from reoperation at 5 years was 97.1% in group B and 97.8% in group M (P = .88). On propensity-score adjusted analyses, there were no significant differences in overall survival between groups.ConclusionsThere were no significant differences in overall survival between bioprosthetic valves and mechanical valves in patients on hemodialysis undergoing AVR.     

老年风湿性二尖瓣病变行二尖瓣修复术与生物瓣膜置换术中期效果比较

目的比较60岁以上老年患者风湿性二尖瓣修复(MVP)与生物瓣膜置换(MVR)的中期效果。方法选取2014年1月至2016年1月北京安贞医院瓣膜外科诊疗中心行风湿性二尖瓣修复或生物瓣置换手术的60岁以上老年风湿性二尖瓣病变患者,包括同期行三尖瓣修复术及房颤射频消融术患者;排除合并主动脉瓣手术、冠状动脉旁路移植手术、二次手术患者,最终纳入患者82例。根据二尖瓣手术方式分为二尖瓣修复组(MVP组,25例)和生物瓣置换组(MVR组,57例)。采用Kaplan-Meier法进行生存分析并绘制曲线,通过Log Rank方法比较两组患者5年生存率的差异。结果围手术期全组患者平均年龄(66.37±4.41)岁。54.9%的患者心功能(NYHA分级)Ⅲ级。两组患者在体外循环时间(P=0.99),主动脉阻断时间(P=0.88),术后住院时间(P=0.76)差异均无统计学意义。MVR组3例患者住院期间死亡,病死率5.3%;MVP组无住院期死亡(P=0.24)。随访5年,最长随访63个月,平均随访47.03个月。MVR组6例死亡,其中4例死于心脑血管不良事件,2例死于非心脑血管不良事件。MVP组无死亡。两组均无再手术病例。结论风湿性二尖瓣病变的老年患者采用二尖瓣修复手术治疗能够获得较好的中期效果。     

Delayed left ventricular rupture after mitral valve replacement

Posterior left ventricular rupture (LVR) is a serious complication following mitral valve replacement (MVR), especially if occurring postoperatively with the chest already closed or the patient in the intensive care unit. Only one of the patients with this delayed type of LVR reported earlier has been treated successfully. Our experience consists of 4 such complications among 161 MVR patients, the incidence being 2.5%. Two of these patients survived. Mechanical factors seem to constitute the most important etiologic causes for this complication. Immediate reoperation must be performed, and extracorporeal circulation is generally mandatory for successful repair. The reconstruction of the ruptured posterior left ventricular wall in both surviving patients was performed from the epicardial surface of the heart using pledget sutures. The auricle of the left atrium was used to cover the site of the tear when bleeding was not stopped with pledget sutures. It usually seems possible to avoid this complication if all mechanical etiologic factors are taken into consideration. After successful correction, a pseudoaneurysm may arise and, for that reason, a cardiac echo sonography follow-up is recommended.     

Mitral valve replacement in the pediatric age group- a single institution experience

Background  Mitral valve replacement in pediatric patient is a difficult surgical task, with many intraoperative and post-operative considerations. We conducted this study to evaluate the indications and early results of mitral valve replacement in children. Methods  From January 2003 to July 2008, fifty-four children under the age of fifteen years underwent mitral valve replacement at our institution. All children received a mechanical bi-leaflet or tilting disc prosthetic valve. All of them underwent valve replacement on the basis of preoperative echocardiography and intraoperative assessment of valve pathology. Results  Preoperatively 65% of the children were in New York Heart Association (NYHA) class III and 35% of them were in NYHA class IV. The cause of mitral valve disease was chronic rheumatic valve disease in 97% of cases and congenital in 3% of the cases. In the rheumatic group 66% of them had severe mitral regurgitation as predominant lesion. The mean diameter of the implanted valve was 27.17mm. There was no hospital or 30 day mortality. The mean follow-up period was 3.6 years. One patient died after 2 years from a stuck valve. Two other patients required thrombolysis for stuck valves. 53 patients are doing well at last follow up. Conclusions  Mitral valve replacement in children is a safe alternative to valve repair when the morphology is not suitable for repair, with acceptable immediate and early outcomes.     

Randomized,prospective, single blind study comparing posterior versus complete chordal preservation during mitral valve replacement in rheumatics

Introduction The early and late hemodynamic benefit of preserving the annulo-papillary continuity during mitral valve replacement has been demonstrated retrospectively. However few prospective studies have been done in this regard. Methods Forty patients (mean age 28.9 yrs) with rheumatic mitral regurgitation were randomized to undergo either partial (PCP) or total (TCP) chordal preservation. The echocardiographically measured left atrial (LA) size, end diastolic volume (EDV), end systolic volume (ESV), ejection fraction (EF), left ventricular fractional shortening (LVFS), left ventricular systolic internal diameter (LVID (s)), left ventricular diastolic internal diameter (LVID (d)) and left ventricular mass (LVM) values were recorded preoperatively, at discharge and at three months. Between group comparison was made using unpaired student t test. Within group comparison was made using repeated measures of analysis of variance (ANOVA) followed by Tukey’s honestly significantly different (HSD) test. All tests were carried at 5% significance. Results Echocardiogram done at discharge showed decrease in the LA size, ESV, EDV, LVID (d/s) in both groups but it continued to fall at three months only in the TCP group. The EF and LVFS decreased at discharge with PCP and continued to be low at three months whereas in TCP group it fell initially following which there was a marginal improvement at three months. The reduction in the echocardiography parameters did not reach statistical significance at the end of three months in either group, except for the reduction in the LVM. The Left ventricle (LV) mass reduction was noted in both the groups at the time of discharge and at three months. The reduction was however much greater in the TCP group (P < 0.01). Conclusion TCP results in a greater reduction in the LV Mass and improved EF compared to PCP. However there is no statistically significant reduction in LA size, EDV, ESV, LVID (d), and LVID in both the groups at the end of three months.     

胸腔镜辅助与前正中开胸二尖瓣置换术的对比研究

目的 比较胸腔镜辅助与前正中开胸两种方式进行二尖瓣置换术的治疗效果,探讨胸腔镜辅助二尖瓣置换术的可行性.方法 2003年10月至2011年10月,共完成胸腔镜辅助二尖瓣置换术72例,同期完成前正中开胸二尖瓣置换74例,对两组患者的体外循环时间、升主动脉阻断时间、术后呼吸机辅助时间、胸腔引流液量、术后ICU停留时间及术后住院时间等资料进行统计学分析比较.结果 胸腔镜组体外循环时间及升主动脉阻断时间较前正中开胸时间长,且差异具有统计学意义.但两组患者的术后呼吸机辅助时间和术后ICU停留时间差异无统计学意义.胸腔镜组的胸腔引流液量少于前正中开胸组,差异具有统计学意义.结论 只要严格把握好适应证,胸腔镜辅助二尖瓣置换术可以作为常规手术开展.     

Mycobacterium fortuitum sternal wound infection following mitral valve replacement

Mycobacterium fortuitum infection of the sternum following cardiac surgery is a rare occurrence.It is usually diagnosed late and has a considerable mortality. We present a female patient with mycobacterium fortuitum sternal wound infection following mitral valve replacement, who was successfully managed with radical surgical debridement combined with multidrug antibiotics. Multidrug antibiotic therapy is essential because of the emergence of resistant strains.